Gene synthesis stands today as one of the most consequential enabling technologies in the life sciences. The global market reached $3.0 billion in 2025 and is projected to more than double to $7.2 billion by 2031, expanding at a compound annual growth rate of 16.1% between 2026 and 2031. Behind those numbers lies more than half a century of scientific development — from painstaking manual chemistry in university laboratories to automated chip-based platforms capable of producing billions of oligonucleotides in parallel on a single chip.
This article traces that development, moving from the earliest experimental work in DNA synthesis through successive waves of commercialization and technical refinement, and arriving at the highly sophisticated, globally distributed industry that exists today.
The story of gene synthesis begins not with biology but with chemistry. The dominant synthesis method that underpinned commercial DNA production for decades — phosphoramidite-based solid-phase synthesis — relies on step-wise chemical coupling of nucleotide building blocks on a solid support. Each cycle adds a single base to a growing chain.
This approach, refined across the 1970s and 1980s, gave researchers the first practical route to producing defined DNA sequences in the laboratory. The chemistry is precise and reproducible, but it carries inherent constraints: harsh organic solvents, chemical waste requiring careful disposal, and an error rate that accumulates with sequence length, making very long constructs difficult to produce cleanly. These limitations defined much of the subsequent innovation agenda for the field.
Polymerase chain reaction, developed in the mid-1980s, gave gene synthesis a powerful complement. By enzymatically amplifying and assembling nucleotide sequences, PCR-based enzyme synthesis offered a route to high-fidelity, economical DNA sequence generation that avoided some of the error accumulation inherent in purely chemical approaches. Advances in high-fidelity DNA polymerases extended the utility of this method further, enabling longer constructs with fewer misincorporations.
The 1990s saw early commercialization of DNA synthesis services, with companies beginning to offer custom oligonucleotide production to academic and pharmaceutical customers. As the Human Genome Project gathered pace and sequencing data accumulated, the demand for defined synthetic DNA sequences to probe and manipulate genomic information grew steadily. Gene synthesis moved from specialist research technique toward an increasingly routine laboratory service.
Two converging forces reshaped the market in the first decade of this century. First, synthesis costs fell sharply as automation, process improvements, and competition among service providers drove down per-base pricing, opening the market to smaller laboratories and a wider range of applications. Second, synthetic biology emerged as a coherent discipline, with researchers engineering biological systems from standardized genetic parts — an ambition that required the ability to design and produce large quantities of custom DNA constructs from scratch.
Chip-based synthesis, using semiconductor or microarray architectures to produce thousands of oligonucleotides simultaneously, emerged as a transformative development during this era. Rather than synthesizing sequences one at a time, chip platforms enabled massively parallel production at substantially lower cost per sequence, making large-scale gene library construction practical. This technology would go on to become the fastest-growing synthesis method in the current market.
CRISPR-Cas9 genome editing, arriving in the early 2010s, acted as another platform shift. Precise genomic cuts depended on guide RNA sequences synthesized to specification, creating immediate and recurring demand for gene synthesis at scale. Alongside CRISPR, the long-promised clinical era of gene and cell therapy began to materialize — CAR-T cell therapies, viral vector-based gene delivery systems, and gene correction approaches for rare diseases all required substantial volumes of precisely synthesized DNA. The market was no longer primarily a research tool business; it was becoming embedded in clinical and manufacturing workflows with fundamentally different quality and regulatory requirements.
The period immediately preceding the current forecast marks a clear acceleration. In 2023, the U.S. FDA approved five novel gene therapies for rare genetic diseases and nine cell and gene therapies in total — a record year that included the first two adoptive cell therapies for solid tumors. That regulatory throughput translated directly into greater demand for synthesized DNA, from viral vectors to plasmid constructs required for manufacturing.
Infrastructure investment followed at multiple levels. In January 2024, the CZS Centre for Synthetic Genomics was established with $13.7 million in financing from the Carl Zeiss Foundation, uniting Heidelberg University, Karlsruhe Institute of Technology, and Johannes Gutenberg University Mainz to develop AI-enabled tools for long DNA synthesis and synthetic genomics. Also in 2024, Human Technopole in Milan opened five specialized national facilities including genomics and genome engineering platforms. China advanced AI adoption for synthetic biology, DNA sequence design, and protein engineering under its Green Biological Manufacturing and Synthetic Biology Key Projects, with approximately $4 billion invested in domestic biotechnology across 2024 and 2025.
Commercial moves reshaped industry structure through 2025 and into 2026. In May 2025, Twist Bioscience and Ginkgo Bioworks reorganized their strategic partnership under a three-year agreement extending access to intellectual property related to long-DNA synthesis. In June 2025, the United Kingdom launched the Synthetic Human Genome Project with approximately $13–14 million in Wellcome funding, led by Jason Chin and drawing on researchers from Imperial College London, the University of Cambridge, the University of Oxford, and the University of Manchester. In November 2025, Bharat Biotech founded Nucelion Therapeutics, a specialized cell and gene therapy CRDMO facility in Genome Valley, Hyderabad, producing viral vectors, plasmids, and advanced therapeutic products. April 2026 brought GenScript Biotech Corporation's strategic partnership with Mimulus Corp. to industrialize DNA-based data storage, with plans to scale from millions to billions of oligonucleotides synthesized in parallel on a single chip. In June 2026, Merck KGaA agreed to acquire Bio-Techne Corporation for an enterprise value of $11.3 billion, strengthening its position across multi-omics, cell and gene therapy, precision diagnostics, and advanced research tools.
The gene synthesis market is valued at $3.0 billion in 2025 and is forecast to reach $7.2 billion by 2031, growing at 16.1% CAGR over the 2026–2031 period.
Among synthesis technologies, solid-phase synthesis remains dominant at $1.3 billion in 2025, holding a 42.5% revenue share and growing at 16.2% CAGR. Chip-based synthesis, at $1.0 billion, is projected to grow fastest at 16.6% CAGR due to its ability to produce thousands of oligonucleotides simultaneously at lower cost. PCR-based enzyme synthesis contributes $702.6 million at 15.0% CAGR.
On the application side, gene and cell therapy development leads at $1.0 billion in 2025 with a 16.5% CAGR. Disease diagnosis contributes $588.4 million at 15.6% CAGR, driven by genomic testing, precision medicine, and rapid production of pathogen-specific sequences for diagnostic development. In services, antibody DNA synthesis holds the largest share at $1.5 billion and 16.2% CAGR, reflecting rapid expansion in monoclonal antibodies, bispecific antibodies, and antibody drug conjugates. Viral DNA synthesis, at $854.0 million and 16.5% CAGR, is the fastest-growing service segment.
North America leads all regions with 41.0% of the global market — $1.2 billion in 2025 — supported by a well-established biotechnology ecosystem, significant NIH funding, and the presence of companies including Twist Bioscience, IDT, and GenScript. Europe is the second-largest region at $889.3 million, with Germany the largest European market at $275.7 million and the United Kingdom at $213.4 million. Asia-Pacific is the fastest-growing region at 17.3% CAGR, led by China at $267.4 million growing at 17.6% CAGR and India at 17.9% CAGR.
Enzymatic DNA synthesis represents the most significant near-term technical transition. Unlike conventional phosphoramidite chemistry, enzymatic approaches build DNA under mild aqueous conditions, reducing chemical waste and hazardous reagent handling. EDS is advancing in synthesis speed, sequence length, and cost-effectiveness, with applications spanning gene therapy manufacturing, mRNA vaccine production, and challenging synthetic biology constructs. Ligase-based synthesis, a related enzymatic approach, offers higher fidelity and easier incorporation of chemical modifications, with growing relevance for metabolic engineering, genome editing, and NGS library preparation.
Ultra-long synthetic DNA platforms — now capable of producing sequence-perfect clonal constructs up to 50 kilobases, deliverable in 25 days or fewer — open application frontiers in synthetic genomics, metabolic engineering, and next-generation cell and gene therapies that previous methods could not address. AI and machine learning integration compounds this capability: algorithms that optimize codon usage, predict secondary DNA structures, and identify problematic sequence patterns before synthesis begins reduce cost and compress development timelines, while cloud-based bioinformatics platforms automate sequence design and synthesis management at scales that would have required large specialist teams a decade ago.
The expansion of synthetic biology beyond healthcare — into industrial biotechnology, agricultural genomics, biofuel production, and DNA-based data storage — continues to widen the addressable market. Challenges remain real: a shortage of multidisciplinary talent in synthetic biology and bioinformatics, biosecurity screening requirements, chemical waste obligations, and research funding cycles all create friction. These are manageable constraints rather than ceiling conditions, but they will shape competitive dynamics and consolidation patterns through the forecast period.
Gene synthesis has traveled a remarkable distance — from the manually intensive chemical procedures of the 1970s to a $3.0 billion global industry embedded in the most advanced areas of medicine, biology, and biotechnology. Each generation of technical innovation, from PCR-based assembly to chip-based parallel synthesis to the enzymatic platforms now emerging, extended what researchers and manufacturers could accomplish while reducing what it cost to do so.
The next six years will likely bring as much change as the previous decade, driven by enzymatic synthesis methods, AI-enabled design tools, ultra-long DNA capability, and a broadening application base stretching from rare disease gene therapy to DNA data storage. The companies, research institutes, and national programs that built the foundations described here are already positioned at the center of that expansion.
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.